PAPER Koers EJ, López-Deber MP, Weingarth M, Nand D, Hickman DT, Mlaki Ndao D, Reis P, Granet A, Pfeifer A, Muhs A, Baldus M
SEARCH RESULTS
331009 RESULTS
PAPER Binnewijzend MA, Adriaanse SM, van der Flier WM, Teunissen CE, de Munck JC, Stam CJ, Scheltens P, van Berckel BN, Barkhof F, Wink AM
Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers.
Hum Brain Mapp. 2013 Sep 3; PubMed: 24039033PAPER Xu X, Wang Y, Wang L, Liao Q, Chang L, Xu L, Huang Y, Ye H, Chen C, Shen X, Zhang F, Ye M, Wang Q, Duan S
Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer's disease.
PLoS One. 2013;8(9):e73129. PubMed: 24039871PAPER Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M
Early Indications of Future Cognitive Decline: Stable versus Declining Controls.
PLoS One. 2013;8(9):e74062. PubMed: 24040166PAPER Ridge PG, Koop A, Maxwell TJ, Bailey MH, Swerdlow RH, Kauwe JS, Honea RA,
Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease.
PLoS One. 2013;8(9):e74158. PubMed: 24040196PAPER Luna S, Cameron DJ, Ethell DW
Amyloid-β and APP Deficiencies Cause Severe Cerebrovascular Defects: Important Work for an Old Villain.
PLoS One. 2013;8(9):e75052. PubMed: 24040383PAPER Martin BA, Allen PA
Where do we stand on the relationship between tau biomarkers and mild cognitive impairment?
Quant Imaging Med Surg. 2013 Aug;3(4):189-91. PubMed: 24040613Kumar Sambamurti on Proteomics Point to RNA Splicing Defects in Alzheimer’s
COMMENT This is a truly exciting advance. While the small RNA world has captured the attention of the field, the global spicing failure is very novel and has been ignored since the days of KPI containing APP forms. It is curious that the authors saw a large incre
Jürgen Götz on Proteomics Point to RNA Splicing Defects in Alzheimer’s
COMMENT This is interesting also in the context of our finding that in the presence of tau the splicing factor SFPQ is relocalized from the nucleus to the cytoplasm. j.goetz 0 Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's
RG7129
THERAPEUTICS Roche RO5508887 BACE Inhibitor Small Molecule Amyloid-Related Three Phase 1 trials have been completed. In January 2012, a trial conducted in Strasbourg, France, concluded a test of RG7129 in 50 healthy men to assess safety and pharmacological parameters
Lanabecestat
THERAPEUTICS AstraZeneca Eli Lilly & Co. AZD3293 LY3314814 BACE inhibitor Small Molecule Amyloid-Related In December 2012, AstraZeneca started a Phase 1 study that evaluated the safety and pharmacological effects of single doses of oral AZD3293 in 72 healthy volun
Elenbecestat
THERAPEUTICS Biogen Eisai Co., Ltd. E2609 BACE inhibitor Small Molecule Amyloid-Related By March 2015, eight Phase 1 trials had been completed to evaluate the safety and pharmacology of elenbecestat in nearly 500 healthy volunteers and people with early Alzheimer'
Yildiz Kelahmetoglu
Karolinska InstituteSweden
vivian li
United States
Li Dong
United States
Current Filters
No filters selected